Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty


Contact us for more batch information
Select Batch
Resource Download


Catalog No. T0968Cas No. 33069-62-4
Paclitaxel (Taxol) is a natural product and a microtubule polymer stabilizer. Paclitaxel has anti-tumor activity and causes cell death by inducing mitotic arrest, apoptosis, and cell autophagy.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
25 mg$34In Stock
50 mg$48In Stock
100 mg$78In Stock
500 mg$118In Stock
1 g$173In Stock
1 mL x 10 mM (in DMSO)$50In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Paclitaxel"

Product Introduction

Paclitaxel (Taxol) is a natural product and a microtubule polymer stabilizer. Paclitaxel has anti-tumor activity and causes cell death by inducing mitotic arrest, apoptosis, and cell autophagy.
In vitro
METHODS: Human T-cell lymphoblastic leukemia cells CCRF-HSB-2 were treated with Paclitaxel (0.01-1 µM) for 48 h. Cell growth inhibition was detected by MTT.
RESULTS: Paclitaxel dose-dependently inhibited the growth of CCRF-HSB-2 cells with an IC50 of 0.25 µM.[1]
METHODS: Human gastric cancer cells AGS were treated with Paclitaxel (10-160 nM) for 24-48 h. The expression levels of target proteins were detected by Western Blot.
RESULTS: Paclitaxel induced the up-regulation of the expression of cleaved caspase-3 and cleaved PARP, which are apoptosis-related proteins. [2]
METHODS: Canine mammary tumor cells CHMm were treated with Paclitaxel (0.01-1 μM) for 24 h. Apoptosis was detected using Flow Cytometry.
RESULTS: Paclitaxel dose-dependently induced apoptosis in CHMm cells. [3]
In vivo
METHODS: To investigate the effect of low-dose Paclitaxel on tumor invasion, Paclitaxel (2.6 mg/kg) was administered intraperitoneally to SCID mice bearing cholangiocarcinoma tumor EGI-1 once daily for two weeks.
RESULTS: Low-dose Paclitaxel treatment reduced the pulmonary spread of EGI-1 cells without significantly affecting their local tumor growth. [4]
METHODS: To develop a preclinical model of Paclitaxel alcohol-induced negative affective symptoms, Paclitaxel (2-8 mg/kg in 1 volume ethanol+1 volume Emulphor-620 +18 volumes distilled water) was injected intraperitoneally into C57BL/6J mice every four injections were given to C57BL/6J mice once every two days.
RESULTS: 8 mg/kg Paclitaxel treatment resulted in the development and maintenance of mechanical and cold abnormalities of pain. Paclitaxel also induced anxiety-like and depressive-like behaviors. Paclitaxel produced behavioral changes in the mouse affective state modeling assay, whereas the increase in injurious responses lasted longer. [5]
Kinase Assay
To determine which caspases are involved in apoptosis induced by taxol, caspase-3 inhibitor (DEVD-CHO), caspase-6 inhibitor (Z-VEID-FMK), caspase-8 inhibitor (Z-IETD-FMK or IETD-CHO), caspase-9 inhibitors (Z-LEHD-FMK or LEHD-CHO), and caspase-10 inhibitor (Z-AEVD-FMK) are used. These caspase inhibitors are dissolved in dimethyl sulfoxide (Me2SO); the final concentration of Me2SO is 0.1%. Cells (5×105) are preincubated in the presence or absence of 100 μM?each of these inhibitors for 3 h at 37°C then treated with or without 0.1, 0.5, and 1 μM?Paclitaxel for 48 h and processed for annexin V binding assay [1].
Cell Research
1×10^4 cells are plated in 100 μL of the growth medium in the presence or absence of increasing concentrations (0.1-1 μM) of taxol in 96-well plates and cultured at 37°C in 5% CO2 for 12-48 h. The cells are then incubated with 25 μL of MTT (5 mg/mL) at 37°C for 4 h. After dissolving the crystals with 0.04 N HCl in isopropanol, the plates are read in a microplate reader at 570 nm [1].
Animal Research
Adult (250-320 g) male Sprague-Dawley rats are used for all experiments. One week following the DiI injection, rats are anesthetized with isofluorane and injected into the tail vein with 2 mg/kg paclitaxel or its vehicle (1:1:23, cremophor EL:ethanol:0.9% saline). The tail vein injection is repeated three more times every other day for a total of four injections [4].
AliasTaxol, NSC 125973
Chemical Properties
Molecular Weight853.91
Cas No.33069-62-4
Storage & Solubility Information
Storagekeep away from direct sunlight,store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: 21.4 mg/mL (25 mM)
DMSO: 85.4 mg/mL (100 mM)
5% DMSO+95% Saline: 4.27 mg/mL (5 mM, precipitation)
Solution Preparation Table
DMSO/5% DMSO+95% Saline
1 mM1.1711 mL5.8554 mL11.7108 mL58.5542 mL
5 mM0.2342 mL1.1711 mL2.3422 mL11.7108 mL
10 mM0.1171 mL0.5855 mL1.1711 mL5.8554 mL
20 mM0.0586 mL0.2928 mL0.5855 mL2.9277 mL
50 mM0.0234 mL0.1171 mL0.2342 mL1.1711 mL
100 mM0.0117 mL0.0586 mL0.1171 mL0.5855 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.